EUVIMEDEUVIMED entdecken
Crossref

Safety and efficacy of nirmatrelvir and ritonavir in kidney transplant recipients with COVID-19

Yadi Wang, Keqin Zhang, Ling Liu, Maozhi Tang, Ming Tang, Linguo Shen, Qiongyao Peng, Bangqin Hu, Zhengsheng Rao

Clinical Nephrology · 01.08.2026 · 106 (2) · 96-109

DOI: 10.5414/cn111815 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Nephrology, erschienen am 01.08.2026. Verfasst von Yadi Wang und 8 weiteren Autor:innen. Hauptthemen laut MEDLINE: Ritonavir, Kidney Transplantation, COVID-19, COVID-19 Drug Treatment.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RitonavirKidney TransplantationCOVID-19COVID-19 Drug TreatmentAntiviral AgentsHumansFemaleRetrospective StudiesMaleMiddle AgedTreatment OutcomeGlomerular Filtration RateImmunosuppressive AgentsAgedSARS-CoV-2Drug Combinations

Substanzen

RitonavirImmunosuppressive AgentsAntiviral AgentsDrug Combinations

Zitieren

APA

Wang, Y., Zhang, K., Liu, L., Tang, M., Tang, M., Shen, L., Peng, Q., Hu, B., & Rao, Z. (2026). Safety and efficacy of nirmatrelvir and ritonavir in kidney transplant recipients with COVID-19. Clinical Nephrology, 106(2), 96-109. https://doi.org/10.5414/cn111815

Vancouver

Wang Y, Zhang K, Liu L, Tang M, Tang M, Shen L, et al. Safety and efficacy of nirmatrelvir and ritonavir in kidney transplant recipients with COVID-19. Clinical Nephrology. 2026;106(2):96-109. doi:10.5414/cn111815

BibTeX
@article{Wang2026,
  author = {Wang, Yadi and Zhang, Keqin and Liu, Ling and Tang, Maozhi and Tang, Ming and Shen, Linguo and Peng, Qiongyao and Hu, Bangqin and Rao, Zhengsheng},
  title = {Safety and efficacy of nirmatrelvir and ritonavir in kidney transplant recipients with COVID-19},
  journal = {Clinical Nephrology},
  year = {2026},
  volume = {106},
  number = {2},
  pages = {96--109},
  doi = {10.5414/cn111815}
}
Kostenlos starten →